02181.HK
Mabpharm Limited
HKSE · Healthcare · Biotechnology · CN
HKD 0.39
−7.14%Year over year
Reported trailing growth
- Revenue
- +80.2%
- EBITDA
- +234.2%
- EBIT
- +253.4%
- EPS
- +406.0%
- Free cash flow
- -66.7%
- Operating cash flow
- -3.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +124.1%
- EBITDA
- +192.8%
- EBIT
- +103.9%
- Net income
- +143.5%
- EPS
- +143.5%
- Free cash flow
- +63.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026